Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Repare Therapeutics Inc (RPTX)

Repare Therapeutics Inc (RPTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 56,115
  • Shares Outstanding, K 42,511
  • Annual Sales, $ 51,130 K
  • Annual Income, $ -93,800 K
  • EBIT $ -96 M
  • EBITDA $ -101 M
  • 60-Month Beta 0.71
  • Price/Sales 1.10
  • Price/Cash Flow N/A
  • Price/Book 0.32

Options Overview Details

View History
  • Implied Volatility 586.98% ( +268.80%)
  • Historical Volatility 251.18%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 586.98% on 12/20/24
  • IV Low 12.00% on 08/16/24
  • Put/Call Vol Ratio 3.13
  • Today's Volume 33
  • Volume Avg (30-Day) 143
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 2,203
  • Open Int (30-Day) 1,157

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.83
  • Number of Estimates 4
  • High Estimate -0.73
  • Low Estimate -1.05
  • Prior Year -0.67
  • Growth Rate Est. (year over year) -23.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2250 +7.76%
on 12/18/24
4.0695 -67.56%
on 12/11/24
-1.5200 (-53.52%)
since 11/20/24
3-Month
1.2250 +7.76%
on 12/18/24
4.0695 -67.56%
on 12/11/24
-2.2000 (-62.50%)
since 09/20/24
52-Week
1.2250 +7.76%
on 12/18/24
8.4900 -84.45%
on 02/12/24
-5.1700 (-79.66%)
since 12/20/23

Most Recent Stories

More News
From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Despite significant advances in oncology research, challenges remain as the American Cancer Society...

ONCY : 0.8310 (-6.36%)
PYXS : 1.6900 (+9.74%)
RPTX : 1.3200 (unch)
IMRX : 2.00 (+8.70%)
CVM : 0.7299 (-4.60%)
ONC.TO : 1.19 (-9.16%)
Alberta Enterprise Corporation invests US$7.5 million into Amplitude precision medicine fund

/CNW/ - Alberta Enterprise Corporation (AEC) announced today that it has invested US$7.5 million into Amplitude Ventures' US$192-million Fund II to give early...

RPTX : 1.3200 (unch)
Amplitude Ventures Closes $263 Million Precision Medicine Venture Fund

/CNW/ - Amplitude Ventures, a full-stack venture capital firm focused on investing in precision medicine at the intersection of biology and AI, today announced...

RPTX : 1.3200 (unch)
Wall Street Thinks This Cathie Wood Stock Could Jump by 187%

This small-cap biotech stock holds enormous growth potential.

TSLA : 421.06 (-3.46%)
ROKU : 80.59 (+2.75%)
SHOP : 108.95 (+1.76%)
RPTX : 1.3200 (unch)
Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Susan Molineaux, Ph.D., to its Board...

RPTX : 1.3200 (unch)
Repare Therapeutics Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors at the 2023 AACR Annual Meeting

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today presented initial data from its ongoing Phase 1/2 TRESR clinical...

RPTX : 1.3200 (unch)
Repare Therapeutics Announces Plenary Oral Presentation at the 2023 AACR Annual Meeting on Camonsertib and Additional Data Presentations on RP-6306

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the data from the Phase I/II trials evaluating camonsertib...

RPTX : 1.3200 (unch)
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended...

RPTX : 1.3200 (unch)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repare Therapeutics Inc. - RPTX

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ: RPTX). Such...

RPTX : 1.3200 (unch)
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Repare Therapeutics Inc. (RPTX) Investigation

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Repare Therapeutics Inc. (“Repare” or the “Company”) (NASDAQ: RPTX). Investors...

RPTX : 1.3200 (unch)

Business Summary

Repare Therapeutics Inc. is an oncology company. It utilizes genome-wide, CRISPR-enabled SNIPRx(R) platform to discover and develop targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's product pipeline includes RP-3500, which is in clinical stage. Repare...

See More

Key Turning Points

3rd Resistance Point 1.5633
2nd Resistance Point 1.5067
1st Resistance Point 1.4133
Last Price 1.3200
1st Support Level 1.2633
2nd Support Level 1.2067
3rd Support Level 1.1133

See More

52-Week High 8.4900
Fibonacci 61.8% 5.7148
Fibonacci 50% 4.8575
Fibonacci 38.2% 4.0002
Last Price 1.3200
52-Week Low 1.2250

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar